<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-06-01T10:19:18Z</responseDate><request verb="GetRecord" identifier="oai:riuma.uma.es:10630/36161" metadataPrefix="rdf">https://riuma.uma.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:riuma.uma.es:10630/36161</identifier><datestamp>2026-02-03T11:22:23Z</datestamp><setSpec>com_10630_2254</setSpec><setSpec>col_10630_37953</setSpec></header><metadata><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:riuma.uma.es:10630/36161">
      <dc:title>(+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice</dc:title>
      <dc:creator>González-Mariscal, Isabel</dc:creator>
      <dc:creator>Carmona-Hidalgo, Beatriz</dc:creator>
      <dc:creator>Winkler, Matthias</dc:creator>
      <dc:creator>Unciti-Broceta, Juan D.</dc:creator>
      <dc:creator>Escamilla-Sánchez, Alejandro</dc:creator>
      <dc:creator>Gómez-Cañas, María</dc:creator>
      <dc:creator>Fernández-Ruiz, Javier</dc:creator>
      <dc:creator>Fiebich, Bernd L.</dc:creator>
      <dc:creator>Romero-Zerbo, Silvana Yanina</dc:creator>
      <dc:creator>Bermúdez Silva, Francisco Javier</dc:creator>
      <dc:creator>Collado, Juan A.</dc:creator>
      <dc:creator>Muñoz, Eduardo</dc:creator>
      <dc:subject>Histología</dc:subject>
      <dc:description>Natural cannabidiol ((-)-CBD) and its derivatives have increased interest for medicinal applications due to their broad biological activity spectrum, including targeting of the cannabinoid receptors type 1 (CB1R) and type 2 (CB2R). Herein, we synthesized the (+)-enantiomer of CBD and its derivative (+)-CBD hydroxypentylester ((+)-CBD-HPE) that showed enhanced CB1R and CB2R binding and functional activities compared to their respective (-) enantiomers. (+)-CBD-HPE Ki values for CB1R and CB2R were 3.1 ± 1.1 and 0.8 ± 0.1 nM respectively acting as CB1R antagonist and CB2R agonist. We further tested the capacity of (+)-CBD-HPE to prevent hyperglycemia and its complications in a mouse model. (+)-CBD-HPE significantly reduced streptozotocin (STZ)-induced hyperglycemia and glucose intolerance by preserving pancreatic beta cell mass. (+)-CBD-HPE significantly reduced activation of NF-κB by phosphorylation by 15% compared to STZ-vehicle mice, and CD3+ T cell infiltration into the islets was avoided. Consequently, (+)-CBD-HPE prevented STZ-induced apoptosis in islets. STZ induced inflammation and kidney damage, visualized by a significant increase in plasma proinflammatory cytokines, creatinine, and BUN. Treatment with (+)-CBD-HPE significantly reduced 2.5-fold plasma IFN-γ and increased 3-fold IL-5 levels compared to STZ-treated mice, without altering IL-18. (+)-CBD-HPE also significantly reduced creatinine and BUN levels to those comparable to healthy controls. At the macroscopy level, (+)-CBD-HPE prevented STZ-induced lesions in the kidney and voided renal fibrosis and CD3+ T cell infiltration. Thus, (+)-enantiomers of CBD, particularly (+)-CBD-HPE, have a promising potential due to their pharmacological profile and synthesis, potentially to be used for metabolic and immune-related disorders.</dc:description>
      <dc:date>2025-01-13T08:40:17Z</dc:date>
      <dc:date>2025-01-13T08:40:17Z</dc:date>
      <dc:date>2025-01-02</dc:date>
      <dc:date>2021-07-01</dc:date>
      <dc:type>journal article</dc:type>
      <dc:identifier>González-Mariscal I, Carmona-Hidalgo B, Winkler M, Unciti-Broceta JD, Escamilla A, Gómez-Cañas M, Fernández-Ruiz J, Fiebich BL, Romero-Zerbo SY, Bermúdez-Silva FJ, Collado JA, Muñoz E. (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice. Pharmacol Res. 2021 Jul;169:105492. doi: 10.1016/j.phrs.2021.105492. Epub 2021 May 19. PMID: 34019978.</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10630/36161</dc:identifier>
      <dc:identifier>10.1016/j.phrs.2021.105492</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>open access</dc:rights>
      <dc:publisher>Elsevier B.V.</dc:publisher>
   </ow:Publication>
</rdf:RDF>
</metadata></record></GetRecord></OAI-PMH>